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Dyskeratosis congenita (DC) is an inherited poikiloderma which in addition to the skin abnormalities is
typically associated with nail dystrophy, leucoplakia, bone marrow failure, cancer predisposition and other
features. Approximately 50% of DC patients remain genetically uncharacterized. All the DC genes identiﬁed
to date are important in telomere maintenance. To determine the genetic basis of the remaining cases of DC,
we undertook linkage analysis in 20 families and identiﬁed a common candidate gene region on chromosome
16 in a subset of these. This region included the C16orf57 gene recently identiﬁed to be mutated in poikilo-
derma with neutropenia (PN), an inherited poikiloderma displaying signiﬁcant clinical overlap with DC.
Analysis of the C16orf57 gene in our uncharacterized DC patients revealed homozygous mutations in 6 of
132 families. In addition, three of six families previously classiﬁed as Rothmund–Thomson syndrome
(RTS—a poikiloderma that is sometimes confused with PN) were also found to have homozygous C16orf57
mutations. Given the role of the previous DC genes in telomere maintenance, telomere length was analysed
in these patients and found to be comparable to age-matched controls. These ﬁndings suggest that
mutations in C16orf57 unify a distinct set of families which clinically can be categorized as DC, PN or RTS.
This study also highlights the multi-system nature (wider than just poikiloderma and neutropenia) of the
clinical features of affected individuals (and therefore house-keeping function of C16orf57), a possible role
for C16orf57 in apoptosis, as well as a distinct difference from previously characterized DC patients because
telomere length was normal.
INTRODUCTION
The main problem facing any clinician is making an accurate
diagnosis from the symptoms and signs presenting in a par-
ticular individual at a given time point. This is compounded
when several diseases have many overlapping features. This
is exempliﬁed by the ‘inherited poikilodermas’ dyskeratosis
congenita (DC), poikiloderma with neutropenia (PN) and
Rothmund–Thomson syndrome (RTS); the overlapping fea-
tures, particularly the poikiloderma, can often make it difﬁcult
to accurately classify a patient into one of these diagnoses.
DC is often described as being a multi-system bone marrow
failure syndrome characterized by abnormal skin pigmentation
(poikiloderma), nail dystrophy and oral leucoplakia (1). It is
genetically and clinically very heterogeneous with three
modes of inheritance being described: X-linked recessive,
autosomal dominant and autosomal recessive. The causative
mutations have been identiﬁed in some, but not all families
presenting with DC. Six genes have been implicated in
causing DC, and all these are important in telomere mainten-
ance either by telomere elongation (telomerase) or telomere
protection (shelterin). Five genes (DKC1, TERC, TERT,
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been shown to be mutated in some patients with DC. Dyskerin
(DKC1) is the main causative gene in the X-linked form of the
disease (2). Autosomal dominant DC is caused by heterozy-
gous mutations in the core components of telomerase,
namely TERC (the RNA component) (3) and TERT (the enzy-
matic component) (4). Autosomal recessive DC is caused by
biallelic mutations in NOP10, NHP2 (both components of
the small nucleolar ribonucleoprotein particle) and TERT
(5–7). Heterozygous mutations have been described in
TINF2 (TIN2) of the shelterin complex (8). Although some
of these TINF2 mutations are inherited in a dominant
fashion, the majority are de novo (9). These six genes,
however, do not account for all the patients with DC as
 40–50% still remain uncharacterized at the genetic level.
RTS is another rare autosomal recessive poikiloderma. Gen-
erally, it presents in infancy with a characteristic facial rash
(poikiloderma) and heterogeneous clinical features including
short stature, juvenile cataracts, sparse hair, skeletal abnormal-
ities and a predisposition to osteosarcoma. Abnormalities in
gastrointestinal, respiratory and haematological systems have
also been reported. Mutations in RECQL4 (ATP-dependent
DNA helicase Q4) have been identiﬁed in  60% of patients
with RTS (10,11). Two clinical subforms of RTS have been
deﬁned: RTS I is characterized by poikiloderma, ectodermal
dysplasia and juvenile cataracts. RTS II is characterized by
poikiloderma, congenital bone defects and an increased risk
of osteosarcoma in childhood and skin cancer in later life.
RTS II is caused by biallelic mutations in RECQL4, but the
function of this gene in the disease still remains unclear.
RTS I is transmitted in an autosomal recessive manner, but
the genetic aetiology remains unknown (12).
PN, previously described as Navajo poikiloderma, is a third
rare autosomal recessive disorder involving poikiloderma
(13,14). In addition to the skin involvement, it is characterized
by neutropenia, short stature, pachyonychia (nail dystrophy)
and pulmonary disease. There is much debate in the literature
as to the degree of separation between this and RTS which is
the more common hereditary poikiloderma (15,16). Generally,
the RECQL4 mutations that are common to RTS are absent in
PN. Recently, however, the gene C16orf57 has been impli-
cated to cause PN. C16orf57 is a gene that has no known func-
tion, but its encoded product has been suggested to be
interconnected to RECQL4 via the SMAD4 protein (17).
The aim of this study was to identify further genes that are
involved in the pathology of DC. In doing so, an unexpected
link was identiﬁed between the three syndromes mentioned
above; a subset of patients classiﬁed clinically as DC, PN
and RTS are uniﬁed by C16orf57 mutations.
RESULTS
IlluminaTM 6k SNP chip analysis
Previous analysis of 16 consanguineous families using micro-
satellite analysis showed that DC is a very heterogeneous dis-
order (5). In comparative terms, this method is crude in terms
of the resolution obtained, so therefore we screened eight
consanguineous multiplex families with DC using the Illumina
6k SNP chip as well as 12 sporadic individuals to identify
possible smaller overlapping regions of homozygosity that
could have been missed by the larger intervals of microsatel-
lite mapping. Interestingly, one of the families (DCR070)
though enrolled on the DCR in 1999 has subsequently been
reported with a diagnosis of PN, Clericuzio type (18). All
the autosomal SNP data were examined for homozygosity in
the families using Genehunter. Although in each family
several regions with signiﬁcant LOD scores (1.5 or greater
depending on family structure) were observed, there was
only one overlapping region on chromosome 16 that was
common to four families (DCR070, DCR107, DCR224 and
DCR279, including a total of nine affected individuals).
When the data from these four families were combined, a
LOD score of 8.2 was achieved, which is highly signiﬁcant.
This interval was deﬁned as being between SNPs rs1982395
and rs768462 (57668756–60069848bp on GRCh37; Fig. 1).
On further scrutiny of the sporadic cases, it was noted that
three individuals also had a signiﬁcant block of homozygosity
overlapping this interval (DCR106, DCR311 and DCR324).
No other signiﬁcant overlapping intervals were identiﬁed in
the remaining families.
Mutation detection
Using the UCSC genome bioinformatics site (http://genome.
ucsc.edu), 22 genes were found to be in this region, none of
which were obvious candidates. Out of these 22 genes,
snoRNA46, snoRNA50, GINS3 and CSNK2A2 were sequenced,
but no mutation was identiﬁed. A recent paper by Volpi et al.
(17) described a homozygous splicing mutation in the orphan
gene C16orf57, in a large kindred with PN. Owing to the clini-
cal overlap between the published family and our DCR
families, we sequenced this gene in the index case from
DCR070, DCR107, DCR224 and DCR279 as well as the
sporadic individuals from DCR106, DCR311 and DCR324
which also overlapped this interval. Homozygous mutations
were identiﬁed in all patients except DCR311 and DCR324
(Table 1). Where a mutation was observed, the rest of the
family was sequenced for that exon to conﬁrm the presence
of the mutation in the index case and to determine segregation
(Fig. 2).
Screening of the dyskeratosis congenita registry
In light of the new C16orf57 mutations discovered in several
of the families with DC, we then screened additional unchar-
acterized families entered into our dyskeratosis congenita reg-
istry (DCR) by heteroduplex analysis to determine whether
any more individuals had mutations in this gene. The DCR
is a large collection of over 350 families with DC from all
over the world. The genetic basis of  40–50% still remains
unknown, and it was these families that were targeted in the
next screen. In addition, six individuals with a clinical diagno-
sis of RTS we had in our collection were also included in the
screen, with two of the patients being normal for RECQL4
(RECQL4 mutation data were unavailable for the other
patients). As mentioned earlier, RTS is very similar in
presentation to PN and two additional mutations in C16orf57
were described by Volpi et al. in a family with atypical RTS
(17,19). A total of 124 additional patients were analysed,
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with DC and 3 with RTS; Table 1 and Fig. 2). In total,
seven homozygous missense, non-sense or frame-shift
mutations were identiﬁed in nine families affecting 14 individ-
uals (ﬁve of these are novel). One mutation was recurrent in
three families, i.e. c.531delA, p.His179Met fsX86. Apart
from one splice-site mutation, all involve the premature trun-
cation or the generation of a partially scrambled protein
(Fig. 3).
Clinical features
Table 2 lists all the various clinical features in the families
with mutations in C16orf57. The most striking feature is the
presentation of abnormal skin pigmentation (poikiloderma)
at a very young age (all ,6 years) and a low white blood
cell count which is common to all. However, there is a large
degree of overlap between all the patients. All the DCR
patients fulﬁl the criteria for the diagnosis of DC as deﬁned
by Vulliamy et al.( 20), namely the index case presents with
the classical mucocutaneous triad of abnormal skin pigmenta-
tion, nail dystrophy and leucoplakia or has at least two of the
mucocutaneous features combined with hypocellular bone
marrow or two or more of the other somatic abnormalities
known to occur in DC; even DCR070, which has been recently
published as having PN, fulﬁls these criteria (18). The patients
with RTS are slightly atypical in that they do have defects in
the bone marrow compartment, but this is not a new obser-
vation (12,19). The overlap of features suggests that none of
the disease classiﬁcations based on clinical criteria is comple-
tely satisfactory. The unifying feature of a mutation in
C16orf57 now helps to deﬁne a tight subtype of patient
proﬁle that shares early-onset skin pigmentation abnormalities
and haematological abnormalities as well as a range of other
features.
Telomeres are not short in patients with C16orf57
mutations
One of the main deﬁning features of the genetically character-
ized DC is that most of the patients regardless of mutation tend
to have short telomeres compared with age-matched controls.
We therefore selected two methods to investigate this in our
patient cohort. The ﬁrst method used Southern blotting with
a subtelomeric probe speciﬁc to chromosome 7. This method
has been widely reported but does involve a large quantity
of DNA being available. Recently, a new multiplexed PCR
[monochrome multiplex quantitative PCR (MM-qPCR)]-based
method has been described that compares the ratios of a
single-copy gene to telomere length. The advantage of
this method is that it needs much less DNA, so is more
Figure 1. Identiﬁcation of a common region of homozygosity in four families
with DC. (A) Homozygosity of all SNPs on chromosome 16. Black boxes indi-
cate a homozygous call, white spaces heterozygous calls. The red bar indicates
the overlapping region. (B) LOD score plot of families DCR279, DCR070,
DCR224 and DCR107 showing the maximum LOD score of 8.2 on chromo-
some 16.
Table 1. Mutations identiﬁed in C16orf57 in patients in the DCR and RTS
patients
Family Exon Nucleotide Protein
070 2 c.179 del C Pro60Leu fsX54
a
106 4 c.450-2 A.G Splice site
107 5 c.531 del A His179Met fsX86
215 5 c.531 del A His179Met fsX86
224 2 c.258 T.A Tyr86X
279 5 c.531 del A His179Met fsX86
RTS 1 2 c.243 G.A Trp81X
b
RTS 2 2 c.176,177 del GG Gly59Ala fsX2
RTS 3 5 c.541 C.T Gln181X
c., coding nucleotide number from the start of translation; p., protein change,
fsX, frame-shift mutation with number of amino acids before stop (X) codon.
aPreviously reported (21).
bMutation previously described in a family with PN (22).
Figure 2. Pedigrees of families with mutations in C16orf57. Sequence panel
on the left shows the normal trace while the right shows the observed
mutation. The arrow highlights the point of mutation. c., coding nucleotide
number; nd, sample unavailable for analysis; open shape, unaffected individ-
ual; ﬁlled shape, affected individual.
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From our patients with C16orf57 mutations, we only had
enough DNA to perform Southern blot analysis on 6,
whereas we were able to perform the MM-qPCR method on
13 patients. We also performed MM-qPCR analysis on 41
healthy controls to establish a normal range. For comparison,
we analysed 48 of our uncharacterized DC patients by
MM-qPCR, and included previously obtained age-adjusted
(△ Tel) lengths from Southern blots for healthy controls and
patients with known DKC1 mutations. What is clear from
both data sets is that telomere length is normal in all patients
with C16orf57 mutations when compared with the healthy
controls (Fig. 4), with no signiﬁcant difference observed
when either set is analysed using the Mann–Whitney U test.
This group is also quite different from most other DC patients
in terms of the telomere lengths whether the genetic basis is
characterized or not. Although we do not know the function
of C16orf57, it is clear that it is not involved in control of tel-
omere length. It also strengthens the idea that C16orf57
mutations are responsible for a very speciﬁc subtype of
disease whether it is classiﬁed as DC, RTS or PN.
C16orf57 knockdown studies
In light of the lack of functional information relating to the role
of C16orf57 in the cell, we undertook a series of experiments to
determine whether it had any role in cell biology either in terms
of apoptosis or in the cell cycle. All experiments were per-
formed on an unsorted population of HT1080 cells either 7 or
14 days after transduction with viral constructs encoding
either a C16orf57 shRNA or a negative shRNA to observe
the effects of knockdown of the C16orf57 transcript
(Fig. 5A). Unmanipulated HT1080 cells were assayed at the
same time. Apoptosis levels after knockdown with the
C16orf57 shRNA showed a small increase in the proportion
of cells that were either apoptotic or post-apoptotic relative to
either the unmanipulated cells or the cells treated with the
negative shRNA viral construct, suggesting the effect is speciﬁc
to the action of reducing the C16orf57 levels in the cell
(Fig. 5B). Repetition of these experiments show that this
increase in the percentage of cells that are apoptotic following
C16orf57 knockdown, although subtle, is statistically signiﬁ-
cant (Student’s t-test P ¼ 0.016, Supplementary Material,
Table S3). Concomitant with this, the proportion of cells
observed in the G2/M phase of the cell cycle was increased
in the C16orf57 knockdown group (Fig. 5C) relative to the
unmanipulated cells, but this failed to reach signiﬁcance.
DISCUSSION
The principal aim of this study was to determine the genetic
basis of the uncharacterized cases of DC present on the
DCR (London). Linkage analysis using the Illumina 6k SNP
chip in 20 DC families (8 consanguineous multiplex families
and 12 consanguineous families with sporadic cases) enabled
a common candidate region of homozygosity to be established
for a subgroup of these families on chromosome 16 between
SNPs rs1982395 and rs768462 (Fig. 1). As well as providing
strong evidence for a DC locus, this result also provided
additional evidence for genetic heterogeneity as not all
families shared this area of homozygosity.
A recent study by Volpi et al. identiﬁed a mutation in the
orphan gene C16orf57 in a large family with PN. This gene
was in our genetic interval of interest and the phenotype of
PN overlaps signiﬁcantly with DC. Sequence analysis of
C16orf57 in our patients with overlapping genetic homozyg-
osity revealed homozygous mutations in ﬁve of these
families, with the mutations segregating in a recessive
manner. Further screening of an additional 118 DC patients
and 6 RTS patients identiﬁed an additional four homozygous
mutations (one in DC and three in RTS). In total, seven
mutations were identiﬁed, ﬁve of which were novel, includ-
ing one recurrent mutation (c.531delA, p.His179MetfsX86).
The other two mutations were reported during the
Figure 3. Schematic structure of C16orf57.( A) Relative position of the mutations to the exons (grey boxes). (B) Relative protein lengths predicted to remain
after mutation. Text colour relates to disease type: blue, DC; red, RTS; black, PN/DC: bar, correct amino acid sequence; line, mutant amino acid sequence before
stop codon. The effect of the splice-site mutation is not shown because of the lack of appropriate material in which to determine the sequence of the aberrant
transcript.
4456 Human Molecular Genetics, 2010, Vol. 19, No. 22Table 2. Features of individuals with C16orf57 mutations
Identiﬁcation 279 070 224 107 106 215 RT 1 RT 2 RT 3
Diagnosis
(reference)
DC DC/PN (18,21) DC DC DC DC RTS (28) RTS RTS
Mutation H179M fsX86 P60L fsX55 Y86X H179M fsX86 c.450-2A.G H179M
fsX86
ND W81X G59A fsX2 Q181X
Clinical feature
Abnormal skin
(poikiloderma)
1(1y) 1 (1y) 11 1 (1y) 1(4y) 1(6y) 1(1y) 1(1y) 1(1y) 1(1y) 11 1 (,2y) 1 (6m)
Nail dystrophy 1(1y) 1(1y) 1 111 (3y) 1(6y) 1(1y) 1(1y) 1(5y) 11 1
Leucoplakia 11 1
Epiphora ++ + +
Head abnormality Tear duct Tear duct Tear duct Abnormal ear,
hearing loss
Abnormal ear Hair loss Sparse
eyelashes
Nasal bridge Prominent
forehead
Dental problems 11 1 1 1 1 1 1 1
Skeletal Osteoporosis + Osteoporosis
Liver–spleen Enlarged Enlarged
Phimosis +
Pulmonary ++ + + + + +
Cardiac VSD
IUGR +
Short stature + ++ +++ + + +
Low BW ++ + +
Dev delay ++ 1 ++
Cancer AML AML Skin
Blood
Hb N Low N N Low Low N Low N Low N Low N
WBC Neutrophils Low Low Low Low Low Low Low Low Low Low Low Died AML
1988
Low
a Low
a Low
Platelets Low Low Low Low Low Variable N N N N N N N N
Bone marrow N Hypo-cellular Hypo-cellular Hypo-cellular MDS changes
Myeloid
maturation
defect
MDS changes MDS changes MDS
changes
MDS changes Hypo-cellular Hypo-cellular
Immuno-globulins     
Mutations identiﬁed in nine families (14 affected individuals): ﬁve DC families (279, 224, 107, 106, 215), one DC/PN (070), three RTS families (RT1, RT2, RT3).
AML, acute myeloid leucaemia; BM, bone marrow; ND, not determined; Hb, haemoglobin; MDS, myelodysplasia; VSD, ventricular septal defect; WBC, white blood cells; N, normal; plus, feature present; upward arrow, increased levels. Age in brackets is in months (m) or
years (y).
aLow neutrophils and lymphocytes—in all other patients, the low WBC count was mainly due to the low neutrophil count. The pulmonary abnormalities included bronchiectasis (DCR279), chronic pulmonary inﬁltrates (DCR070), pulmonary cystic changes (DCR107),
recurrent chest infections (DCR279, DCR070, RT1) and restrictive lung disease (DCR107). Imaging of the liver in DCR106 and DCR107 showed no evidence of cirrhosis. Bone marrows which showed hypocellularity were usually associated with some features of dysplasia.
BM cytogenetic analyses were undertaken in some patients (DCR070, RT1 and RT2), and these showed no abnormal cytogenetic clones.
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7preparation of this article: the ﬁrst relates to the mutation in
our family DCR070 which has been previously reported as
having PN (18). This mutation published by Tanaka et al.
(21) has been veriﬁed by this work as being c.179delC,
p.Pro60Leu fsX54. The second mutation, c.243G.A,
p.Trp81X, has recently been reported in a family with PN
that is distinct from the family in which we observe this
change (22).
Figure 4. Telomere lengths are not short in patients with mutations in C16orf57 compared with healthy controls. (A) Sample of a Southern blot using the sub-
telomeric probe pTelBam8. This shows the variety of lengths obtained from different individuals both with and without disease. (B) Age-adjusted △ tel values
for controls compared with patients with C16orf57 mutations, uncharacterized patients with DC and patients with known DKC1 mutations. (C) T/S ratio as a
measure of telomere length comparing controls with patients with C16orf57 mutations and uncharacterized DC patients. AA, patient with aplastic anaemia;
Unch, genetically uncharacterized DC patients; Tinf2, DC patient with TINF2 mutation; solid line, median length obtained for the sample group, P-values
from the Mann–Whitney U test relative to controls.
Figure 5. Effects of knockdown of C16orf57 on apoptosis and cell cycle. (A) Levels of knockdown achieved in 7 days after treatment with lentiviral-shRNA. (B)
Corresponding apoptosis levels in HT1080 cells. (C) Corresponding cell cycle analysis. Vertical stripes, unmanipulated cells; horizontal stripes, cells transduced
with a negative shRNA lentiviral construct; solid black bars, cells transduced with a C16orf57 shRNA lentiviral construct. Numbers on graphs relate to the data
point for each experiment.
4458 Human Molecular Genetics, 2010, Vol. 19, No. 22The individuals with C16orf57 mutations have multi-system
abnormalities, as summarized in Table 2. This includes the
striking abnormal skin pigmentation/poikiloderma at a young
age and a low white cell count (particularly the neutrophil
count). In addition, affected individuals have a variable
range of other features which are seen in classical cases of
DC, PN and RTS. It is apparent from this table that a clinician
could diagnose these patients as having any of these three syn-
dromes particularly as the age of onset of some of these fea-
tures is highly variable. Although C16orf57 mutations were
ﬁrst described in a family labelled as PN, it is clear from
Table 2 that C16orf57 mutations produce a wider range of
multi-system abnormalities and not just PN. The multi-system
abnormalities are also more akin to DC and suggest that the
C16orf57 gene is likely to have an important house-keeping
role in the cell. This is also consistent with the ubiquitous
expression proﬁle of C16orf57 in different human tissues
(http://www.genecards.org). Three out of the 14 of patients
have developed a cancer at a young age (acute myeloid leucae-
mia in two, squamous cell carcinoma of the skin in one). Thus,
like other cases of DC and RTS, patients with C16orf57
mutations have a predisposition to developing cancer.
As well as the neutropenia, approximately half of the
patients also have abnormalities in red cell (haemoglobin)
and/or platelet counts. In addition, several of the bone
marrows from these patients suggested a global defect in hae-
matopoiesis either in the form of myelodysplasia or as hypo-
cellularity. Therefore, although there is a major impact on
the myeloid lineage with the consequent neutropenia, there
are features suggestive of a more global haematopoietic
defect. In one RTS patient, with the appropriate sample
being available (RT2), peripheral blood progenitor studies
showed a reduction in both myeloid and erythroid progenitors
(Supplementary Material, Table S2), again providing evidence
for a more global haematopoietic defect. Further investi-
gations are warranted to validate this observation as only the
one patient sample was available.
It is notable that the mutations identiﬁed in these
families all spare the N-terminus of the protein (Fig. 3B).
The smallest mutant protein is predicted to have at least
61 of the N-terminal amino acids. This suggests that an
important key function of the protein may be located
within this part of the molecule. At present, the function
of the gene remains to be elucidated. Our knockdown
studies suggest a subtle but signiﬁcant increase in the pro-
portion of apoptotic cells after knockdown of C16orf57.
These data indicate that C16orf57 might have some role
in controlling apoptosis, although this effect may well be
indirect, possibly via its proposed interaction with
SMAD4 (17). Additional studies need to be performed to
further characterize the function of C16orf57 particularly
in primary cells and the effects of long-term knockdown.
It will also be important to determine the precise effect
each mutation has on the protein.
The previously characterized cases of DC (due to mutations
in DKC1, TERC, TERT, NOP10, NHP2 and TINF2) are associ-
ated with short telomeres (as demonstrated in Fig. 4B, DKC1
lengths). Telomere length was measured in patients by either
Southern blot or MM-qPCR. Telomere length measurements
by any method are highly variable in terms of the range and
a wide overlap can exist between different individuals, as
shown in Fig. 4A. This example shows how lengths vary
and how not all patients with DC have short telomeres. Telo-
mere length was found to be comparable to age-matched con-
trols by both methods and longer than groups of patients either
uncharacterized or with DKC1 mutations. This observation
suggests that patients presenting with features of DC due to
C16orf57 mutations are distinct from those due to mutations
in the previously characterized DC genes. This observation
suggests that telomere length maintenance is unaffected in
this group of patients. It does not however reject telomere dys-
function as the mechanism of disease. This idea has been
suggested previously by Lamm et al. in their study of patients
with Hoyeraal–Hreidarsson syndrome (23), in which they
propose that telomere length-independent pathways can con-
tribute to telomere dysfunction.
In summary, we report the identiﬁcation of novel homozy-
gous mutations in the C16orf57 gene in several families clini-
cally classiﬁed as DC, PN and RTS. The multi-system
abnormalities in the affected individuals include poikiloderma,
haematological abnormalities, a range of other abnormalities
and a predisposition to cancer. These observations suggest a
house-keeping role for this gene, but the precise function at
this stage remains elusive. C16orf57 mutations therefore
unify a speciﬁc subset of patients with multi-system abnorm-
alities observed in DC, PN and RTS but which are distinct
from previously characterized DC patients as they have
normal-length telomeres.
MATERIALS AND METHODS
Patient selection
All of the patients included in this study have been enrolled in
the DCR initially at Hammersmith Hospital and relocated to
Barts and The London in 2006. The clinical criteria used for
entry into this registry have been described previously (20).
In addition to patients with DC, we also included the six
patients in our collection with RTS and any family members
where appropriate. All samples were obtained with informed
consent and with the approval of our local ethics committee.
SNP genotyping and linkage analysis
Genomic DNA samples, prepared from peripheral blood
samples extracted using the Puregene DNA isolation kit
(Gentra, Minneapolis, USA), from 8 consanguineous multi-
plex families and 12 consanguineous families with sporadic
cases were analysed using the Illumina 6k SNP chip (service
provided by The Genome Centre, Barts and The London
School of Medicine). Of the 51 individuals analysed, 27 had
a diagnosis of DC, 14 were unaffected parents and 10 were
unaffected siblings. Multi-point LOD score analysis was per-
formed on each of the families using Genehunter (24), assum-
ing an autosomal recessive inheritance, 100% penetrance and
a disease allele frequency of 0.005.
Mutation screening
Primers (Supplementary Material, Table S1) were designed to
amplify the entire coding region (seven exons) of C16orf57 in
Human Molecular Genetics, 2010, Vol. 19, No. 22 4459the index cases of the families that had an overlapping LOD
score on chromosome 16 (n ¼ 4). These fragments were
sequenced using Applied Biosystems Big dye V3.1 chemistry
on a 3130XL DNA analyser (Applied Biosystems, Warring-
ton, UK). An additional set of primers (available on request)
were designed to screen 118 uncharacterized index case
patient samples in the DCR by denaturing high-performance
liquid chromatography (Transgenomic, Glasgow, UK) at a
single temperature at which the fragment was at least 80%
helical. Samples were pooled pairwise to identify any possible
homozygous changes. Any pools which gave abnormal elution
patterns were re-ampliﬁed separately and sequenced.
Telomere length measurements
Southern blotting. Genomic DNA was digested with BamH1
and analysed by Southern blot using a 0.75% agarose gel
and the subtelomeric probe pTelBam8 (25,26). Telomere
lengths were measured as the size of the fragment of peak
signal intensity, which includes  8kb of subtelomeric DNA.
Sizes were determined with reference to the same standards
run on each gel using Image Quant software. Data from
normal control samples, patients with C16orf57 mutations
and age-adjusted telomere length (△ Tel) values were
obtained as described previously (3). Differences between
the various groups were tested using the Mann–Whitney
U test.
Monochrome multiplex quantitative PCR. Telomere lengths
were measured using a multiplex real-time PCR method
adapted from Cawthon (27). All samples were measured in tri-
plicate. Brieﬂy, each 15 ml of the reaction mixture contained
10 ng of genomic DNA and used the Roche SYBR Green
Master I reaction mix (Roche Applied Science, Burgess Hill,
UK). Telomere-speciﬁc primers were used at a concentration
of 1 mM each and single-copy gene primers (speciﬁc to
human beta-globin) at 200 nM each. Reactions were analysed
on a Roche LightCycler 480 real-time thermal cycler (Roche
Applied Science). A standard curve was established using a
titration of a reference DNA sample and T/S ratios determined
from the curve.
Interfering RNA study
C16orf57 mRNA transcript was knocked-down using a
mission shRNA viral construct (TRCN0000137195; Sigma).
HT1080 (human ﬁbrosarcoma) cells were exposed to either
the C16orf57 shRNA virus or a non-target shRNA virus for
3 days. Cells were subsequently cultured for 7 or 14 days
before being assayed for levels of transcript reduction, apopto-
sis and cell cycle proﬁles relative to unmanipulated cells.
cDNA preparation
RNA was prepared from 0.5 × 10
6 cells from both types of
viral manipulated cells and unmanipulated cells using the
RNeasy mini kit (Qiagen). Following DNase1 (Invitrogen)
treatment to remove any genomic DNA contamination, RNA
was reverse transcribed into cDNA using M-MLV (Invitrogen)
and random hexamer primers (Qiagen) in standard reactions
according to manufacturer protocols.
Quantitative real-time PCR
RNA expression levels were determined by quantitative real-
time PCR on an ABI prism 7500 real-time PCR system
(Applied Biosystems). Twenty microlitre (ﬁnal volume) reac-
tions were performed using SYBR
w Green PCR master mix
(Applied Biosystems), 1 ml of cDNA and 25 nM forward and
reverse primers. C16orf57 was measured using the Taqman
gene expression assay Hs00984813_ml. The ABL gene
expression was used as an endogenous control for normaliza-
tion and expression calculated from standard curves as a
C16orf57/ABL ratio.
Apoptosis
Apoptosis levels were determined using standard ﬂow cytome-
try techniques. Brieﬂy, this involved staining of the apoptotic
membrane marker phosphatidylserine with a ﬂuorescent
annexin V–Alexaﬂuor 647 conjugate and co-staining of
nuclear DNA with 4′,6-diamidino-2-phenylindole (DAPI)
(Invitrogen). These ﬂuorophores were used to avoid interfer-
ence from the GFP expressed by the viral shRNA constructs.
After a 15 min incubation, cells were analysed using an
LSRII four-laser ﬂow cytometer (BD, Oxford, UK).
Cell cycle proﬁle
G0/G1, S and G2M populations were determined using stan-
dard methods. A total of 0.2 × 10
6 cells were ﬁxed overnight
in 70% ethanol, washed twice in PBS and resuspended in
300 ml PBS with 10 mg/ml DAPI and 200 mg/ml RNase
A. Cells were incubated at 378C for 30 min before being ana-
lysed on the ﬂow cytometer. Cells were pulse-width gated to
exclude doublets.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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